全文获取类型
收费全文 | 81318篇 |
免费 | 6088篇 |
国内免费 | 1817篇 |
专业分类
耳鼻咽喉 | 490篇 |
儿科学 | 2747篇 |
妇产科学 | 989篇 |
基础医学 | 4892篇 |
口腔科学 | 767篇 |
临床医学 | 11536篇 |
内科学 | 22498篇 |
皮肤病学 | 305篇 |
神经病学 | 1267篇 |
特种医学 | 1531篇 |
外国民族医学 | 6篇 |
外科学 | 11083篇 |
综合类 | 12860篇 |
现状与发展 | 9篇 |
预防医学 | 5569篇 |
眼科学 | 381篇 |
药学 | 7313篇 |
99篇 | |
中国医学 | 3543篇 |
肿瘤学 | 1338篇 |
出版年
2024年 | 207篇 |
2023年 | 1529篇 |
2022年 | 3016篇 |
2021年 | 4161篇 |
2020年 | 3767篇 |
2019年 | 2936篇 |
2018年 | 2839篇 |
2017年 | 2744篇 |
2016年 | 2864篇 |
2015年 | 2839篇 |
2014年 | 5438篇 |
2013年 | 5901篇 |
2012年 | 4359篇 |
2011年 | 4906篇 |
2010年 | 3846篇 |
2009年 | 3778篇 |
2008年 | 3629篇 |
2007年 | 3784篇 |
2006年 | 3566篇 |
2005年 | 3333篇 |
2004年 | 2834篇 |
2003年 | 2671篇 |
2002年 | 1755篇 |
2001年 | 1675篇 |
2000年 | 1222篇 |
1999年 | 1112篇 |
1998年 | 938篇 |
1997年 | 860篇 |
1996年 | 799篇 |
1995年 | 706篇 |
1994年 | 679篇 |
1993年 | 538篇 |
1992年 | 501篇 |
1991年 | 460篇 |
1990年 | 394篇 |
1989年 | 377篇 |
1988年 | 349篇 |
1987年 | 281篇 |
1986年 | 247篇 |
1985年 | 276篇 |
1984年 | 207篇 |
1983年 | 128篇 |
1982年 | 154篇 |
1981年 | 131篇 |
1980年 | 98篇 |
1979年 | 97篇 |
1978年 | 85篇 |
1977年 | 60篇 |
1976年 | 54篇 |
1975年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
55.
《The Journal of arthroplasty》2022,37(7):1338-1347
BackgroundMultimodal pain therapy combining analgesics, local infiltration analgesia (LIA) and peripheral nerve blocks, such as fascia iliaca compartment block (FICB), can improve postoperative pain, nausea and vomiting (PONV) and ambulation in patients undergoing total hip arthroplasty (THA). We hypothesized that addition of FICB would decrease opioid requirements and length of stay (LOS) but could create a motor block.MethodsThis is a single center, prospective, blinded randomized controlled study of 152 patients undergoing elective THA via direct anterior approach from October 2019 till August 2021. Three patient groups were defined: patients receiving only spinal anesthesia (control group, n = 53); spinal anesthesia with LIA perioperatively (n = 50); and spinal anesthesia with FICB on the recovery unit (n = 49). Outcome measures consisted of postoperative pain scores, PONV, length of hospital stay, opioid requirements and mobility.ResultsOverall pain scores were low for all patient groups, with a lower pain score for LIA in comparison to the control group until 4 hours postoperatively (P < .05). Length of hospital stay, postoperative pain, nausea and vomiting (PONV) scores and quadriceps muscle strength did not differ significantly between groups. The control group showed higher scores at 12 hours postoperatively in comparison to FICB regarding rehabilitation potential, use of walking aids and activities of daily living (P < .05), but all groups reached the same endpoint 48 hours postoperatively. The LIA and FICB groups required less opioids until 24 hours postoperatively.ConclusionLIA is a beneficial adjuvant therapy to spinal anesthesia in THA patients as it may decrease pain scores and the need for opioid consumption. Adjuvant FICB only provided lower opioid requirements. 相似文献
56.
目的通过研究肺表面活性物质(PS)结合持续气道正压通气(CPAP)治疗新生儿呼吸窘迫综合征(NRDS)的治疗效果,进一步指导NRDS的临床治疗。方法选取于2017年4月-2018年10月间在本院收治的80例确诊为新生儿呼吸窘迫综合征的患儿作为研究对象,随机将患儿分为试验组和对照组,对照组给予持续气道正压通气治疗,试验组在对照组的基础上联合使用PS治疗。结果试验组对于呼吸窘迫缓解的有效率明显高于对照组,在气管插管内滴入PS治疗后试验组的血气情况明显优于对照组,且试验组患儿副作用发生率明显低于对照组,以上指标差异具有统计学意义,P <0.05。结论 PS结合CPAP在新生儿呼吸窘迫综合征的治疗中疗效很好。 相似文献
57.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2020,32(6):347-353
The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at higher risks of severe infection from the illness. In addition, staff illness and restructuring of services to deal with the crisis will inevitably place treatment capacities under significant strain. These guidelines aim to expand on those provided by NHS England regarding cancer care during the coronavirus pandemic by examining the known literature and provide guidance in managing patients with urothelial and rarer urinary tract cancers. In particular, they address the estimated risk and benefits of standard treatments and consider the alternatives in the current situation. As a result, it is recommended that this guidance will help form a framework for shared decision making with patients. Moreover, they do not advise a one-size-fits-all approach but recommend continual assessment of the situation with discussion within and between centres. 相似文献
58.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献
59.
60.